Journal
ORAL ONCOLOGY
Volume 39, Issue 4, Pages 397-401Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S1368-8375(02)00144-6
Keywords
amifostine; oral candidiasis; radiotherapy; xerostomia
Categories
Ask authors/readers for more resources
This controlled study assessed the incidence of oral candidiasis, a xerostomia-related complication, in head and neck cancer patients receiving radiotherapy, with amifostine cytoprotection. Thirty-eight patients received 500 mg arnifostine i.v., prior to each radiotherapy fraction, while 16 patients received radiotherapy alone. Oral candidiasis was diagnosed according to the criteria described before. Subjective xerostomia scales were completed by all patients. Mucositis was evaluated using the RTOG criteria. Oral candidiasis was diagnosed in 11/38 arnifostine patients and in 9/16 controls (P=0.07). Severe xerostomia was reported by 4/38 arnifostine patients and by 7/16 controls. Oral candidiasis was reduced with amifostine cytoprotection. Oral candidiasis is suggested as an objective, early, though indirect, endpoint for amifostine's radioprotective effect on salivary glands. (C) 2003 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available